Achieve Life Sciences, Inc. (ACHV)
收市後：
| 前收市價 | 4.5750 |
| 開市 | 4.5700 |
| 買盤 | 4.5800 x 400 |
| 賣出價 | 4.6400 x 400 |
| 今日波幅 | 4.4900 - 4.6400 |
| 52 週波幅 | 3.0300 - 10.3000 |
| 成交量 | |
| 平均成交量 | 93,958 |
| 市值 | 157.901M |
| Beta 值 (5 年，每月) | 1.28 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.5000 |
| 業績公佈日 | 2024年5月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 19.75 |
Insider MonkeyAchieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2023 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2023 Earnings Call Transcript March 28, 2024 Achieve Life Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the Achieve Life Sciences Fourth Quarter and Year-End 2023 Earnings Conference Call […]
- Insider Monkey
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2023 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2023 Earnings Call Transcript November 9, 2023 Achieve Life Sciences, Inc. reports earnings inline with expectations. Reported EPS is $-0.34 EPS, expectations were $-0.34. Operator: Greetings. Welcome to Achieve Life Sciences Third Quarter Earnings Conference Call and Webcast. [Operator Instructions] Please note this conference is being recorded. At this […]
BenzingaCan't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial
Achieve Life Sciences Inc (NASDAQ: ACHV) announced topline results from the second Phase 3 ORCA-3 trial of cytisinicline. Consistent with the previously reported Phase 3 ORCA-2 study, ORCA-3 showed a statistically significant benefit in helping people to quit smoking compared to placebo, with low rates of adverse events. The 6- and 12-week cytisinicline treatment durations demonstrated statistically significant smoking cessation on the primary and secondary efficacy analyses compared to placebo.
